CD19-directed CAR T cells gain traction

Affiliations

¹ Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Perelman Center for Advanced Medicine, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA. Electronic address: stephen.schuster@uphs.upenn.edu.

Comment

Stephen J Schuster. Lancet Oncol. 2019 Jan.

. 2019 Jan;20(1):2-3.

doi: 10.1016/S1470-2045(18)30900-8. Epub 2018 Dec 2.

¹ Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Perelman Center for Advanced Medicine, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA. Electronic address: stephen.schuster@uphs.upenn.edu.

No abstract available

Comment on

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Locke FL, et al. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. Lancet Oncol. 2019. PMID: 30518502 Free PMC article. Clinical Trial.